Cargando…

Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?

Detalles Bibliográficos
Autores principales:	Lemoli, Roberto M., D'Addio, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Hematologia e Hemoterapia 2011
Materias:	Scientific Comments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415742/ https://www.ncbi.nlm.nih.gov/pubmed/23049286 http://dx.doi.org/10.5581/1516-8484.20110044

Ejemplares similares

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment
por: Zhou, Shiyuan, et al.
Publicado: (2023)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
por: Gao, Fei, et al.
Publicado: (2021)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Comment on “Outcomes of autologous transplantation for multiple myeloma according to different induction regimens”
por: de la Rubia, Javier
Publicado: (2014)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
por: Chen, S., et al.
Publicado: (2022)

Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
por: Nguyen, Ai-Hoc, et al.
Publicado: (2022)

Busulfan‐containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study
por: Wang, Yu‐Hung, et al.
Publicado: (2021)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia
por: Shi, Yuan-Yuan, et al.
Publicado: (2023)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

Single-Agent High-Dose Melphalan as Conditioning Regimen in Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma: Safety, and Long-Term Efficacy
por: Al Hashmi, Hani, et al.
Publicado: (2018)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

Peripheral hematopoietic progenitor cell mobilization for autologous transplantation in hematologic malignancies
por: Marques Jr, José Francisco Comenalli
Publicado: (2011)

The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
por: Mardani, Masoud, et al.
Publicado: (2020)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Murthy, Guru Subramanian Guru, et al.
Publicado: (2023)

Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency
por: Lum, S. H., et al.
Publicado: (2019)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Comment on: clinical impact of systematic nutritional care in adults submitted to allogeneic hematopoietic stem cell transplantation
por: Daudt, Liane Esteves
Publicado: (2012)

Comment on “Nutritional status of patients submitted to transplantation of allogeneic hematopoietic stem cells: a retrospective study”()
por: Schmidt, Erin M., et al.
Publicado: (2014)

Phase-2 Trial of an Intensified Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Poor-Risk Leukemia
por: Stein, Anthony S., et al.
Publicado: (2010)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

Impact of conditioning regimen on peripheral blood hematopoietic cell transplant
por: Burns, Michael, et al.
Publicado: (2019)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning
por: Germeraad, R. S., et al.
Publicado: (2022)

Metabolic Potential of the Gut Microbiome Is Significantly Impacted by Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
por: Jørgensen, Mette, et al.
Publicado: (2022)

Use of Busulfan to Condition Mice for Bone Marrow Transplantation
por: Montecino-Rodriguez, Encarnacion, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ih023v9pknqdqpqlnqbnnhek63